After US Approval, BeiGene Set To Gain Sixth PD-1 Green Light In China
But Is Sector Becoming Overcrowded?
Beijing-based BeiGene is set to score two big wins in a row as it pursues innovation. After securing US approval for its BTK inhibitor zanubrutinib for mantle cell lymphoma, its PD-1 inhibitor has sailed through a technical review in China.
